Sentry Page Protection
Gui Zhi Fu Ling Wan 桂枝茯苓丸
Cinnamon twig and Poria Pill
Cinnamon twig and Poria Pill
Gyejibongnyeong-Hwan (Korean)
Keishi-bukuryo-gan (Japan)
Keishi-bukuryo-gan (Japan)
Tradition:
TCM
Source / Author:
Essential of the Golden Cabinet, c. 220
|
Herb Name
Gui Zhi (Cinnamon twig)
Fu Ling (Poria) Bai Shao yao (White Peony) Mu Dan Pi (Tree peony root) Tao Ren (Peach kernel) |
|
Preparation:
Powder and form Pills.
Today it is frequently used in the form of decoction with the above amounts being used per day.
Also made into tinctures.
Function:
Moves the Blood, clears Stasis, Resolves Masses
Use:
Blood stasis in the Uterus; pain, dark blood, dark tongue with whitish coating
1. Abdominal pain
2. Masses in the lower abdomen
3. Amenorrhea; Dysmenorrhea; Mittelschmerz
4. Chronic infection or inflammation of the Uterus
5. Endometriosis
6. Menopause syndrome
7. Irregular Menstruation with dark blood and pain; persistent Uterine Bleeding
8. Considered specific by some for Ovarian Cysts; Uterine Fibroids
9. Masses or lumps of the prostate or testes; Chronic Prostatitis
10. Hyperplasia of the Breasts
11. Infertility
Dose:
3– 6 grams of the powder can be taken 3 times daily, preferably with wine.
If used as a decoction, the above can be taken over the course of the day
Cautions:
1. Used cautiously during pregnancy (best to use only pills or powder during pregnancy)
Modifications:
1. Severe blood stasis, add Rhubarb and Madder
2. More severe menstrual pain and cramping, add Cyperus rotundus
3. For Fibroids, Agaric (Fomes) can replace Poria Fu Ling as it has a similar nature but is much stronger to resolve Fibroids. However, in cases with deficiency, Poria Fu Ling is superior.
Nothing at the moment
Nothing at the moment
INHIBITS PLATELET AGGREGATION:
–Keishibukuryogan, a Traditional Japanese Medicine, Inhibits Platelet Aggregation in Guinea Pig Whole Blood.
DYSMENORRHEA
–Deciphering the Pharmacological Mechanisms of Guizhi-Fuling Capsule on Primary Dysmenorrhea Through Network Pharmacology.
–Effect of Guizhi Fuling Wan in primary dysmenorrhea: A randomized controlled trial.
–[Mechanism Study on Danggui Shaoyao San and Guizhi Fuling Wan For Treating Primary Dysmenorrheal Based on Biological Network].
POLYCYSTIC OVARY SYNDROME
–Guizhi Fuling Wan inhibits autophagy of granulosa cells in polycystic ovary syndrome mice via H19/miR-29b-3p.
–Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway.
–Efficacy of different forms of Guizhi Fuling Wan on reproduction and metabolism in women with polycystic ovary syndrome: A protocol for a meta-analysis of randomized controlled trials.
UTERINE FIBROIDS:
–Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids.
–Guizhi Fuling Wan for uterine fibroids: A systematic review of in vivo studies.
–A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids.
PELVIC INFLAMMATORY DISEASE:
–Guizhi Fuling wan for chronic pelvic inflammatory disease protocol: A protocol for systematic review and meta analysis.
–[Guizhi Fuling capsule / pill treatment for chronic pelvic inflammatory disease：a systematic review of randomized clinical trials].
ENDOMETRIOSIS
–Combinatory effects of current regimens and Guizhi Fuling Wan on the development of endometriosis.
–Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis.
–High-throughput metabolomics used to identify potential therapeutic targets of Guizhi Fuling Wan against endometriosis of cold coagulation and blood stasis.
MENOPAUSE:
–Beneficial effect of Gyejibokryeong-hwan on climacteric syndrome with blood stasis pattern: A randomized, double-blinded, placebo-controlled clinical pilot trial.
–A Classic Herbal Formula Guizhi Fuling Wan for Menopausal Hot Flushes: From Experimental Findings to Clinical Applications.
–Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial.
OVARIAN CANCER
–A Chinese classical prescription Guizhi-Fuling Wan in treatment of ovarian cancer: An overview.
–Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway.
PROSTATE CANCER TREATMENT SIDE EFFECTS:
–Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy.
MELANOMA:
–Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p.
SUDURAL HEMATOMA:
–Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma - Prospective observational study.
–Keishibukuryogan, a Traditional Japanese Medicine, Inhibits Platelet Aggregation in Guinea Pig Whole Blood.
DYSMENORRHEA
–Deciphering the Pharmacological Mechanisms of Guizhi-Fuling Capsule on Primary Dysmenorrhea Through Network Pharmacology.
–Effect of Guizhi Fuling Wan in primary dysmenorrhea: A randomized controlled trial.
–[Mechanism Study on Danggui Shaoyao San and Guizhi Fuling Wan For Treating Primary Dysmenorrheal Based on Biological Network].
POLYCYSTIC OVARY SYNDROME
–Guizhi Fuling Wan inhibits autophagy of granulosa cells in polycystic ovary syndrome mice via H19/miR-29b-3p.
–Guizhi Fuling Wan reduces autophagy of granulosa cell in rats with polycystic ovary syndrome via restoring the PI3K/AKT/mTOR signaling pathway.
–Efficacy of different forms of Guizhi Fuling Wan on reproduction and metabolism in women with polycystic ovary syndrome: A protocol for a meta-analysis of randomized controlled trials.
UTERINE FIBROIDS:
–Randomized double-blind trial comparing low dose and conventional dose of a modified traditional herbal formula Guizhi Fuling Wan in women with symptomatic uterine fibroids.
–Guizhi Fuling Wan for uterine fibroids: A systematic review of in vivo studies.
–A network pharmacology approach to investigate the pharmacological effects of Guizhi Fuling Wan on uterine fibroids.
PELVIC INFLAMMATORY DISEASE:
–Guizhi Fuling wan for chronic pelvic inflammatory disease protocol: A protocol for systematic review and meta analysis.
–[Guizhi Fuling capsule / pill treatment for chronic pelvic inflammatory disease：a systematic review of randomized clinical trials].
ENDOMETRIOSIS
–Combinatory effects of current regimens and Guizhi Fuling Wan on the development of endometriosis.
–Utilizing network pharmacology and molecular docking to explore the underlying mechanism of Guizhi Fuling Wan in treating endometriosis.
–High-throughput metabolomics used to identify potential therapeutic targets of Guizhi Fuling Wan against endometriosis of cold coagulation and blood stasis.
MENOPAUSE:
–Beneficial effect of Gyejibokryeong-hwan on climacteric syndrome with blood stasis pattern: A randomized, double-blinded, placebo-controlled clinical pilot trial.
–A Classic Herbal Formula Guizhi Fuling Wan for Menopausal Hot Flushes: From Experimental Findings to Clinical Applications.
–Effect of Guizhifulingwan (Keishibukuryogan) on climacteric syndrome: study protocol for a randomized controlled pilot trial.
OVARIAN CANCER
–A Chinese classical prescription Guizhi-Fuling Wan in treatment of ovarian cancer: An overview.
–Guizhi Fuling Wan, a Traditional Chinese Herbal Formula, Sensitizes Cisplatin-Resistant Human Ovarian Cancer Cells through Inactivation of the PI3K/AKT/mTOR Pathway.
PROSTATE CANCER TREATMENT SIDE EFFECTS:
–Efficacy and safety of keishibukuryogan, a traditional Japanese Kampo medicine, for hot flashes in prostate cancer patients receiving androgen deprivation therapy.
MELANOMA:
–Guizhi Fuling pills inhibit the proliferation, migration and invasion of human cutaneous malignant melanoma cells by regulating the molecular axis of LncRNA TPT1-AS1 / miR-671-5p.
SUDURAL HEMATOMA:
–Japanese herbal Kampo medicine, Keishibukuryogan, for chronic subdural hematoma - Prospective observational study.